Dana-Farber team identifies new 'gene traffic control' targets in two rare, aggressive cancers
Cigall Kadoch has long known that synovial sarcoma, a rare cancer of soft tissues, is caused by changes in a complex of proteins that regulates chromatin. In fact, she’s based her whole career on and founded a biotech company around the binding material used to package DNA into cells, or the “gene traffic control” as she prefers to call it. Now, her team at Dana-Farber Cancer Institute has pinpointed one specific “molecular machine” that they believe to be responsible for not only synovial sarcoma but also another rare but very aggressive cancer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
